Absorption of therapeutic agents across mucosal membranes or the skin

Abstract

Absorption of a therapeutic agent across a mucosal membrane or the skin can be enhanced using an absorption enhancer comprising a hydroxy fatty acid ester of polyethylene glycol.

Description

[0001]This application is a division of U.S. patent application Ser. No. 13 / 063,411, which is a U.S. national stage entry under 35 U.S.C. §371 of International Patent Application No. PCT / GB2009 / 051188, filed Sep. 14, 2009, which claims priority from Great Britain Patent Application No. 0816642.3, filed Sep. 12, 2008 and Great Britain Patent Application No. 0820799.5, filed Nov. 13, 2008.FIELD OF THE INVENTION[0002]This invention relates to the enhancement of absorption of therapeutic agents across mucosal membranes or the skin. In particular, the invention concerns the use of a hydroxy fatty acid ester of polyethylene glycol for enhancing transmucosal or transdermal delivery of a pharmaceutically active therapeutic agent. The invention also relates to compositions and methods for administration of a pharmaceutically active therapeutic agent to a mucosal membrane or the skin.BACKGROUND OF THE INVENTION[0003]Administration of therapeutic agents to the mucosa is well known in the art. ...

AI Technical Summary

Benefits of technology

The present invention provides a way to deliver therapeutic agents to the respiratory tract and nasal or buccal cavities through mucosal membranes. This mode of delivery has several advantages, including the ability to avoid degradation from stomach acid, bile, and other first-pass effects. It allows for quicker onset of action, lower dosing, and more accurate dosing. The invention also includes a pharmaceutical composition containing a therapeutic agent and an absorption enhancer, which can be in the form of a spray, powder, or tablet for nasal, buccal, or oral delivery. The invention improves the delivery of oral drugs by allowing them to be better transported across the gastrointestinal tract.

Problems solved by technology

Despite the advantages of mucosal routes of delivery, many therapeutic agents, such as peptides and proteins and hydrophilic small molecular weight drugs, are poorly absorbed across a mucosal membrane due to their physicochemical characteristics (eg large molecular weight, hydrophilicity, lability), and must therefore be administered by injection or infusion.

For some of these drugs, such as insulin administered to type 1 diabetics, a multiple daily dosing by injection is necessary and results in non-compliance, especially among younger patients (Drug Discovery Today, 7, 2002, 1184-1189; J Control Rel, 87, 2003, 187-198).

In particular, agents of large molecular weight and / or high hydrophilicity are poorly absorbed across mucosal membranes.

This is a particular problem for biologic drugs or “biologics”, such as peptides and proteins, polynucleic acids, SiRNA, RNA and antigens, since these are mostly large molecular weight molecules of a polar nature.

A further problem regarding the delivery of biologics, is that biologics are prone to degradation by enzymes such as peptidases and proteases, especially when administered via the gastrointestinal tract.

However, absorption enhancers employed previously in nasal studies, such as salicylates, bile salts and bile salt derivatives, phospholipids and lysophospholipids, sodium lauryl sulphate and cyclodextrins and chitosan derivatives, have in some cases been shown to result in irritation or damage to the mucosal membrane.

A variety of other mucosal absorption enhancer systems have been developed to deliver therapeutic agents across a mucosal membrane, but problems reported have included irritation, malabsorption and clearance of the therapeutic agent preventing successful absorption into the systemic circulation.

Many excipients such as polyethylene glycol and glycofurolum (U.S. Pat. No. 5,397,771) can be highly viscous and therefore unsuitable for intranasal and mucosal delivery.

The high solubility of colchicines means that the increase in oral absorption is unlikely to be due to increased drug solubility in the intestinal fluids due to Solutol.

Such uses have, however, been restricted to the solubilisation of poorly soluble drugs and / or inhibition of P-Gp and CYP450.

However, transdermal delivery is also hampered by the problems mentioned above for drug delivery across mucosal membranes.

The skin's low permeability limits the number of drugs that can be delivered in this manner, with the result that many hydrophilic compounds and / or compounds of high molecular weight are not currently deliverable by the transdermal route.

Without the use of absorption enhancers, many drugs will not diffuse into the skin at a sufficient rate to obtain therapeutic concentrations.

A particular concern for transdermal delivery is the possibility that a local irritation will develop at the site of application.

Images